Victor Golmer
Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, bad news for Pfizer's (PFE) danuglipron and uncertainty about whether Medicare will reimburse for the medications.
Obesity drug developers Verve Therapeutics (